Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Antiviral Therapy|November 15, 2000
In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugsS Rusconi, D P Merrill, S La Seta Catamancio, et al.Infection|June 30, 2014
Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010G Sulis, I El Hamad, M Fabiani, et al.Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.Journal of Biological Regulators and Homeostatic Agents|April 14, 2000
Prevalence of HIV-1 resistant strains in recent seroconvertersC Balotta, A Berlusconi, A Pan, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 30, 2013
Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)S Rusconi, F Adorni, B Bruzzone, et al.AIDS (London, England)|October 6, 1999
CD4 cell counts at the third month of HAART may predict clinical failureA d'Arminio Monforte, V Testori, F Adorni, et al.Antimicrobial Agents and Chemotherapy|January 1, 1996
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activitiesS Rusconi, M Moonis, D P Merrill, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.Antiviral Therapy|June 10, 2000
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individualsC Balotta, A Berlusconi, A Pan, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2013
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseS Rusconi, P Vitiello, F Adorni, et al.Pageof 10